Kimia Farma Tbk PT
IDX:KAEF

Watchlist Manager
Kimia Farma Tbk PT Logo
Kimia Farma Tbk PT
IDX:KAEF
Watchlist
Price: 600 IDR Market Closed
Market Cap: 3.3T IDR
Have any thoughts about
Kimia Farma Tbk PT?
Write Note

Kimia Farma Tbk PT
Other Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Kimia Farma Tbk PT
Other Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Kimia Farma Tbk PT
IDX:KAEF
Other Current Liabilities
Rp342.9B
CAGR 3-Years
27%
CAGR 5-Years
11%
CAGR 10-Years
14%
T
Tempo Scan Pacific Tbk PT
IDX:TSPC
Other Current Liabilities
Rp499.6B
CAGR 3-Years
13%
CAGR 5-Years
29%
CAGR 10-Years
12%
Kalbe Farma Tbk PT
IDX:KLBF
Other Current Liabilities
Rp970.2B
CAGR 3-Years
-4%
CAGR 5-Years
9%
CAGR 10-Years
7%
Darya-Varia Laboratoria Tbk PT
IDX:DVLA
Other Current Liabilities
Rp83.5B
CAGR 3-Years
17%
CAGR 5-Years
20%
CAGR 10-Years
28%
Soho Global Health Tbk PT
IDX:SOHO
Other Current Liabilities
Rp94.1B
CAGR 3-Years
-10%
CAGR 5-Years
0%
CAGR 10-Years
N/A
Pyridam Farma Tbk PT
IDX:PYFA
Other Current Liabilities
Rp117.9B
CAGR 3-Years
49%
CAGR 5-Years
101%
CAGR 10-Years
42%
No Stocks Found

Kimia Farma Tbk PT
Glance View

Market Cap
3.3T IDR
Industry
Pharmaceuticals

PT Kimia Farma Tbk engages in the production and distribution of healthcare products. The company is headquartered in Jakarta, Dki Jakarta and currently employs 11,668 full-time employees. The company went IPO on 2001-07-04. The firm produces medical devices and chemical materials. The firm is also involved in producing vegetable oil, iodine, and salts. Its products include Glucokaf, Diazink, Oracef, Kifarox, Magacid Suspension, Magaside Chewable Tablets, Nitrocafe Retarded, Nitrocafe Retard Forte, Trinolon, Raistine, VAGIZOL, Neviral, Hiviral Tablet, Duviral, Codipront Cum Expectorant, RETHAPHYL SR, and SUPRAFLU. Its generic products include PETHIDIN Hcl, PARACETAMOL, Diclofenac Sodium, MEPHANAMIC ACID, ANTALGIN, ANTASIDE DOEN, PYRANTEL, ALBENDAZOLE, METRONIDAZOLE TABLET, NEO BLOOD ADDING TABLET, FERROUS SULOATE SYRUP, DIMENHYDRINATE, ACYCLOVIR, AMBROXOL HCL, CHLOROQUINE, CHLORPROMAZINE HCL, CODEIN, CLOPIDOGREL, ERGOTAMINE COFFEE, METHYLERGOMETRINE TABLET SALUTE, MELOXICAM, and Pherphenazine.

KAEF Intrinsic Value
1 038.26 IDR
Undervaluation 42%
Intrinsic Value
Price

See Also

What is Kimia Farma Tbk PT's Other Current Liabilities?
Other Current Liabilities
342.9B IDR

Based on the financial report for Sep 30, 2024, Kimia Farma Tbk PT's Other Current Liabilities amounts to 342.9B IDR.

What is Kimia Farma Tbk PT's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
14%

Over the last year, the Other Current Liabilities growth was -51%. The average annual Other Current Liabilities growth rates for Kimia Farma Tbk PT have been 27% over the past three years , 11% over the past five years , and 14% over the past ten years .

Back to Top